STOCK TITAN

TerrAscend Preannounces Strong Second Quarter 2023 Revenue and Gross Margins and Provides Full Year Guidance

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
TerrAscend Corp. reported record second quarter 2023 net revenue of $72.1 million, up 12.7% YoY and 3.9% sequentially. Gross profit margin increased to 50.2% compared to 48.8% in Q1 2023. The company expects full year 2023 net revenue of at least $305 million and adjusted EBITDA of $58 million. The earnings conference call is scheduled for August 10, 2023.
Positive
  • TerrAscend Corp. achieved record second quarter net revenue of $72.1 million, representing a 12.7% YoY increase and a 3.9% sequential increase.
  • The company's gross profit margin improved to 50.2% in Q2 2023, compared to 48.8% in Q1 2023.
  • TerrAscend expects full year 2023 net revenue to be at least $305 million, reflecting a 23% YoY growth, and adjusted EBITDA of $58 million, indicating a 49% YoY growth.
Negative
  • None.

Record second quarter 2023 Net Revenue of $72.1 million, up 12.7% year-over-year and 3.9% sequentially, representing the 7th consecutive quarter of sequential growth

Gross Profit Margin increased to 50.2% compared to 48.8% in Q1 2023

Company expects full year 2023 Net Revenue and Adjusted EBITDA from continuing operations1 of at least $305 million and $58 million, respectively

Second quarter 2023 earnings conference call scheduled for August 10, 2023 at 5 p.m. ET

TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced preliminary and unaudited financial results for its second quarter ended June 30, 2023. All amounts are in U.S. dollars.

Based on a preliminary and unaudited review, the Company anticipates:

  • Net Revenue of $72.1 million, an increase of 12.7% year-over-year and 3.9% sequentially
  • Gross Profit Margin increased to 50.2% compared to 48.8% in Q1 2023 and 37.5% in Q2 2022

Additionally, the Company expects Net Revenue and Adjusted EBITDA from continuing operations1 for full year 2023 will be at least $305 million and $58 million, respectively, representing year over year growth of 23% in Net Revenue and 49% in Adjusted EBITDA from continuing operations1.  

“We are pleased to deliver results in the second quarter that exceeded our internal forecasts. This team has accomplished a tremendous amount in recent months. We have significantly improved our margins, transformed our balance sheet, materially lowered our interest expense, achieved positive cashflow, acquired four dispensaries in Maryland, and successfully listed on the TSX, all while driving sector leading revenue growth,” stated Jason Wild, Executive Chairman of TerrAscend. “These achievements bolster our confidence in the remainder of the year. As evidenced by today’s guidance, we expect significant growth in revenue and profitability as we realize the benefit of our now vertically integrated operations in Maryland as well as continued strong execution in our other geographies.”

1Adjusted EBITDA from continuing operations is a non-GAAP measure. Please see discussion of non-GAAP measures at the end of this press release. TerrAscend is not able, at this time, to provide a reconciliation of Adjusted EBITDA for full year 2023 to net (loss)/income from continuing operations because of the unreasonable effort of estimating on a forward-looking basis certain items that are excluded from Adjusted EBITDA from continuing operations, including, for example, certain material non-cash items such as inventory write downs outside of the normal course of operations, share based compensation expense, impairment charges taken on goodwill, intangible assets and property and equipment, the gain or loss recognized on the revaluation of our contingent consideration liabilities, one-time write off of accounts receivable related to one customer that was deemed uncollectible, loan modification fees related to the modification of debt, the gain recognized on the extinguishment of debt, the gain or loss recognized on the remeasurement of the fair value of the U.S denominated preferred share warrants, one time fees incurred in connection with acquisitions and certain other adjustments management believes are not reflective of the ongoing operations and performance, the effect of which may be significant. The outlook for full year 2023 provided above is forward-looking in nature. Actual results may differ materially. See the cautionary note regarding “Forward-Looking Information” below.

Conference Call Details:
The Company will report its full financial results for the second quarter ended June 30, 2023 on Thursday, August 10, 2023 after market close. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss its financial results for the second quarter 2023.

Date:Thursday, August 10, 2023
Time:5:00 p.m. Eastern Time
RapidConnect URL:https://emportal.ink/44mrcy0
Webcast:Click Here
Dial-in Number:1-888-664-6392
Conference ID:98441769
Replay:



416-764-8677 or 1-888-390-0541

Available until 12:00 midnight Eastern Time Thursday, August 24, 2023
Replay Entry Code: 441769#

About TerrAscend Corp.
TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including vertically integrated operations in Pennsylvania, New Jersey, Maryland, Michigan and California through TerrAscend Growth Corp. and retail operations in Canada through TerrAscend Canada Inc. (“TerrAscend”). TerrAscend operates The Apothecarium, Gage and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com

Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.

Notice Regarding Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits. Examples of forward-looking information contained in this press release include statements regarding the impacts of the expectations of the Company’s future financial and operational performance, including the outlook for full year 2023; and expectations for other economic, business, and/or competitive factors.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com and in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2023, as may be amended by the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2022 filed with the SEC on May 4, 2023 and its subsequently filed quarterly reports on Form 10-Q.

Definition and Reconciliation of Non-GAAP Measures

In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company's ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, Adjusted EBITDA from continuing operations and Adjusted EBITDA Margin from continuing operations are calculated as EBITDA from continuing operations adjusted for certain material non-cash items such as inventory write downs outside of the normal course of operations, share based compensation expense, impairment charges taken on goodwill, intangible assets and property and equipment, the gain or loss recognized on the revaluation of our contingent consideration liabilities, one-time write off of accounts receivable related to one customer that was deemed uncollectible, loan modification fees related to the modification of debt, the gain recognized on the extinguishment of debt, the gain or loss recognized on the remeasurement of the fair value of the U.S denominated preferred share warrants, one time fees incurred in connection with our acquisitions and certain other adjustments management believes are not reflective of the ongoing operations and performance. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. The Company believes this definition is a useful measure to assess the performance of the Company as it provides more meaningful operating results by excluding the effects of expenses that are not reflective of the Company's underlying business performance and other one-time or non-recurring expenses.

The statements in this press release are made as of the date of this press release. TerrAscend disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For more information regarding TerrAscend:
Keith Stauffer
Chief Financial Officer
717-343-5386
IR@terrascend.com

Briana Chester
MATTIO Communications
424-465-4419
terrascend@mattio.com

 


FAQ

What were TerrAscend Corp.'s second quarter 2023 net revenue and gross profit margin?

TerrAscend Corp. reported net revenue of $72.1 million in Q2 2023, with a gross profit margin of 50.2%.

What is the company's outlook for full year 2023 net revenue and adjusted EBITDA?

TerrAscend expects full year 2023 net revenue to be at least $305 million and adjusted EBITDA to be $58 million.

When is the earnings conference call scheduled?

The earnings conference call is scheduled for August 10, 2023.

TERRASCENT CORP

OTC:TSNDF

TSNDF Rankings

TSNDF Latest News

TSNDF Stock Data

283.41M
235.85M
7.06%
5.79%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Mississauga